Kyle Doherty

Articles

NCCN Releases First Neuroblastoma Treatment Recommendations

February 12th 2024

The NCCN has published the first set of treatment recommendations for neuroblastoma.

PRAME Shows Promise as a Treatment Avenue in Melanoma, Other Solid Tumors

February 12th 2024

Preferentially expressed antigen in melanoma has emerged as a target for treatment development in multiple solid tumors.

Data From 2023 ASH Annual Meeting Provide Positive Updates in Multiple Myeloma

February 11th 2024

Experts discuss treatment in newly diagnosed multiple myeloma and the role of CAR T-cell therapies and bispecifics in relapsed/refractory disease.

Trabectedin Monotherapy Does Not Improve OS vs Chemotherapy in BRCA-Mutated Recurrent Ovarian Cancer

February 9th 2024

Trabectedin did not offer a survival benefit vs chemotherapy in recurrent ovarian cancer with BRCA-mutated and/or BRCAness phenotype.

Goserelin Included in Latest NCCN Breast Cancer Guidelines

February 7th 2024

The NCCN Breast Cancer Panel has included goserelin at 2 dosing schedules as a method for ovarian function suppression in their updated guidelines.

Early-Phase Clinical Research Center Poised to Provide New Benefits in Hawaii and Beyond

February 7th 2024

The University of Hawaii Cancer Center hopes to address treatment needs through its planned Early Phase Clinical Research Center.

EGFR-Targeted TKIs Continue to Have Outsized Impact in NSCLC

February 6th 2024

Thomas J. Lynch Jr, MD, details how treatments are evolving for patients with EGFR-mutated advanced non–small cell lung cancer.

A-Plus Machine Learning Approach Displays Accurate Cancer Detection With Smaller Sample Amounts

February 2nd 2024

Investigators have developed a machine learning algorithm that could eventually facilitate earlier cancer detection via smaller blood draws.

SABCS 2023 Findings Build on Positive Momentum in HER2+ Breast Cancer

February 1st 2024

Expert oncologists in the field of breast cancer review data in HER2-positive early-stage and metastatic breast cancer.

sBLA Submitted to FDA for Subcutaneous Daratumumab Plus VRd in Transplant-Eligible Multiple Myeloma

January 31st 2024

A sBLA seeking the approval of D-VRd for transplant-eligible patients with newly diagnosed multiple myeloma was submitted to the FDA.

Phase 2 Study of Denifanstat Looks to Add First-in-Class Agent to HER2+Breast Cancer Treatment Armamentarium

January 30th 2024

Phase 2 trial investigators hope denifanstat can be a key component in restoring sensitivity to HER2- positive metastatic breast cancer treatments.

Subcutaneous Nivolumab Provides Clinical Equipoise to Standard IV Dosing in ccRCC

January 27th 2024

Subcutaneous nivolumab coformulated with rHuPH20 demonstrated noninferiority of PK exposures vs intravenous nivolumab in metastatic ccRCC.

FDA Requests Class-Wide Boxed Warning for CAR T-Cell Agents Regarding Secondary T-Cell Malignancy Risk

January 25th 2024

The FDA has called to add a class-wide boxed warning for CAR T-cell therapies to alert patients of the risk of developing secondary T-cell malignancies.

NECTIN-4 Offers Attractive Target in Urothelial Cancer and Beyond

January 24th 2024

As the treatment paradigm in urothelial cancer expands to include agents directed at various targets, NECTIN-4 has emerged as a promising treatment target.

Data From ESMO 2023 Further Define Treatment Paradigm in Advanced Melanoma

January 23rd 2024

Oncologists reviewed data from clinical trials in the field of melanoma that could add clarity to treatment standards and lead to improved patient care.

Olverembatinib Added to NCCN Guidelines for CML

January 22nd 2024

Olverembatinib has been added to the NCCN's latest 2024 guidelines for management of chronic myeloid leukemia.

Tiragolumab Plus Atezolizumab and Chemotherapy Offers Survival Benefit Over Chemotherapy Alone in ESCC

January 19th 2024

Tiragolumab plus atezolizumab and chemotherapy produced superior survival benefit vs chemotherapy for patients with esophageal squamous cell carcinoma.

Tampa General Hospital Cancer Institute Celebrates 2 Years of Growth and Innovation

January 19th 2024

Tampa General Hospital Cancer Institute has experienced much growth since its establishment, in terms of attracting talent and expanding their footprint.

Frontline Camrelizumab/Rivoceranib Combination Shows Promise in Unresectable HCC

January 17th 2024

Amit Mahipal, MD, discusses data on camrelizumab plus rivoceranib in advanced HCC and the phase 3 CARES-310 trial, which is currently enrolling patients.

GB2064 Displays Preliminary Efficacy, Tolerability in Myelofibrosis

January 16th 2024

GB2064 displayed efficacy with a generally acceptable tolerability profile in the treatment of patients with myelofibrosis.